Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
CD40L (human) (multimeric) (rec.) (Certified Serum Grade)
1700
CHF
CHF 1'700.00
In stock
AG-40B-0010CSG-C100100 µgCHF 1'700.00
| Product Details | |
|---|---|
| Synonyms | MultimericCD40L™; ACRP30headless:CD40L; ACRP30headless:CD154; ACRP30headless:TNFSF5; ADIPOQ-CD40L |
| Product Type | Protein |
| Properties | |
| Source/Host | CHO cells. Produced using certified serum/medium.* |
| Sequence |
Human CD40L (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag. |
| Crossreactivity | Human |
| Specificity |
Binds to human CD40. |
| Biological Activity |
Induces B cells activation (as demonstrated by dose-dependent upregulation of CD86) (ED50: <1ng/ml). B cell expansion online protocol available. |
| MW | ~35-40kDa (SDS-PAGE) |
| Purity | ≥95% (SDS-PAGE) |
| Endotoxin Content | <0.01EU/μg purified protein (LAL test, Lonza). |
| Concentration | 1mg/ml |
| Formulation | Liquid. Contains PBS. |
| Other Product Data |
UniProt link P29965: CD40L (human) FLAG is a registered trademark of Sigma-Aldrich Co. |
| Declaration | *Certified Serum Grade: Produced using certified high-quality FBS grade serum. Specifications of FBS include Traceability/Source, Sterile Filtered, Virus, Mycoplasma & Endotoxin Tested, Osmolality and Cell Culture Tested, Inactivation by γ-Irradiation. |
| Shipping and Handling | |
| Shipping | DRY ICE |
| Short Term Storage | -20°C |
| Long Term Storage | -20°C |
| Handling Advice |
Avoid freeze/thaw cycles. PBS containing at least 0.1% BSA should be used for further dilutions. |
| Use/Stability |
Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
MultimericCD40L™ is a high-activity construct in which two trimeric CD40 ligands are artificially linked via the collagen domain of ACRP30. This construct very effectively simulates the natural membrane-assisted aggregation of CD40L in vivo. It provides a simple and equally potent alternative to [CD40L+enhancer] combinations. MultimericCD40L™ has been shown to suppress alum-induced IL-1β release and caspase-1 activation in a dose-, CD40- and time-dependent manner, without affecting BMDM viability. It also effectively suppressed the inflammasome function triggered by NLRP3 activators. The secretion of caspase-1 independent inflammatory mediators has been shown to be unaltered or even enhanced. MultimericCD40L™ has been shown to be a potent tool for B cell expansion. It also has big potential as a growth factor for tumor-infiltrating lymphocytes (TILs), which have been shown to be important for T cell therapy.
Product References
- IgG subclass switch capacity is low in switched and in IgM-only, but high in IgD+IgM+, post-germinal center (CD27+) human B cells: C. Werner-Favre, et al.; Eur. J. Immunol. 31, 243 (2001)
- Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex: N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003)
- Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sezary syndrome: circumvention by hexameric soluble CD40L: L.E. French, et al.; Blood 105, 219 (2005)
- Cysteine-rich Domain 1 of CD40 Mediates Receptor Self-assembly: C.R. Smulski, et al.; J. Biol. Chem. 288, 10914 (2013)
- Sensitive, multiplex and direct quantification of RNA sequences using a modified RASL assay: H.B. Larman, et al.; Nucl. Acids Res. 42, 9146 (2014)
- CD4+ T Cell-derived IL-21 and deprivation of CD40 signaling favor the In Vivo development of granzyme B-expressing regulatory B cells in HIV patients: C. Kaltenmeier, et al.; J. Immunol. 194, 3768 (2015)
- Lenalidomide potentiates CD4+ CD25+ Treg-related suppression of lymphoma B-cell proliferation: M.A. Grygorowicz, et al.; Clin. Exp. Med. 17, 193 (2017)
- CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation: Ch. Jiang, et al.; Cell Rep. 28, 1307 (2019)
- Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes: J. Racle, et al.; Nat. Biotech. 37, 1283 (2019)
- Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes: C. Chong, et al.; Nat. Commun. 11, 1293 (2020)
- Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference: F. Marino, et al.; Front. Immunol. 11, 1981 (2020)
- Detection of alloreactive T cells from cryopreserved human peripheral blood mononuclear cells: N. Tanimine, et al.; J. Immunol. Meth. 491, 112987 (2021)
- Sensitive identification of neoantigens and cognate TCRs in human solid tumors: M. Arnaud, et al.; Nat. Biotechnol. 40, 656 (2022)
Related Products
